Clinical Trial Update: Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating a triple combination of sitravatinib, nivolumab, and ipilimumab in advanced or metastatic clear-cell renal cell carcinoma; the trial st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Sitravatinib (sitravatinib)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Clear-Cell Renal Cell Carcinoma | Phase 1 | Status: COMPLETED